Improving <i>Helicobacter pylori</i> Eradication Regimens
Authors: Fritz Francois, Martin J. Blaser
Journal: Annals of Internal Medicine (2006)

Editorials17 January 2006Improving Helicobacter pylori Eradication RegimensFritz Francois, MD and Martin J. Blaser, MDFritz Francois, MDFrom New York University School of Medicine, New York, NY 10010.Search for more papers by this author and Martin J. Blaser, MDFrom New York University School of Medicine, New York, NY 10010.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-2-200601170-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Helicobacter pylori colonization has known costs to humans, including increased risk for peptic ulcer disease (1), gastric adenocarcinoma (2), and gastric lymphoma (3). The finding that elimination of H. pylori changes the natural history of peptic ulcer disease (4) and gastric mucosa–associated lymphoid tissue lymphoma (5) has led to the development of successful strategies to clear the organism from persons with these disorders. Over the past 20 years, regimens that use acid-suppressing agents in conjunction with several antibiotics (in particular, clarithromycin [6]) have been highly successful for H. pylori eradication (7). However, recent reports detail decreasing efficacy of these combination ...References1. Nomura AM, Pérez-Pérez GI, Lee J, Stemmermann G, Blaser MJ. Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease. Am J Epidemiol. 2002;155:1054-9. [PMID: 12034584] CrossrefMedlineGoogle Scholar2. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132-6. [PMID: 1891021] CrossrefMedlineGoogle Scholar3. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267-71. [PMID: 8145781] CrossrefMedlineGoogle Scholar4. Hentschel E, Brandstätter G, Dragosics B, Hirschl AM, Nemec H, Schütze K, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308-12. [PMID: 8419816] CrossrefMedlineGoogle Scholar5. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999;131:88-95. [PMID: 10419446] LinkGoogle Scholar6. Gisbert JP, González L, Calvet X, García N, López T, Roqué M, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000;14:1319-28. [PMID: 11012477] CrossrefMedlineGoogle Scholar7. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta-analysis. Aliment Pharmacol Ther. 1999;13:857-64. [PMID: 10383518] CrossrefMedlineGoogle Scholar8. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374-84. [PMID: 15306603] CrossrefMedlineGoogle Scholar9. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000;95:3393-8. [PMID: 11151867] CrossrefMedlineGoogle Scholar10. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis. 2003;9:432-7. [PMID: 12702222] CrossrefMedlineGoogle Scholar11. Sjölund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med. 2003;139:483-7. [PMID: 13679325] LinkGoogle Scholar12. Blaser MJ. The genetic gymnastics of our indigenous microbes. N Engl J Med. 2002;346:2083-5. [PMID: 12087147] CrossrefMedlineGoogle Scholar13. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther. 2003;17:719-26. [PMID: 12641522] CrossrefMedlineGoogle Scholar14. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006;144:94-100. LinkGoogle Scholar15. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis. 2003;35:541-5. [PMID: 14567457] CrossrefMedlineGoogle Scholar16. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-80. [PMID: 11860399] CrossrefMedlineGoogle Scholar17. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2005:CD002096. [PMID: 15674892] Google Scholar18. Geographic variation in penicillin resistance in Streptococcus pneumoniae—selected sites, United States, 1997. MMWR Morb Mortal Wkly Rep. 1999;48:656-61. [PMID: 10488781] MedlineGoogle Scholar19. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139:463-9. [PMID: 13679322] LinkGoogle Scholar20. Talley NJ, Vakil N, Ballard ED, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 1999;341:1106-11. [PMID: 10511608] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Fritz Francois, MD; Martin J. Blaser, MDAffiliations: From New York University School of Medicine, New York, NY 10010.Disclosures: None disclosed.Corresponding Author: Fritz Francois, MD, Division of Gastroenterology, New York University School of Medicine, 423 East 23rd Street, Room 11132N, New York, NY 10010; e-mail, fritz.[email protected]nyu.edu.Current Author Addresses: Dr. Francois: Division of Gastroenterology, New York University School of Medicine, 423 East 23rd Street, Room 11132N, New York, NY 10010.Dr. Blaser: New York University School of Medicine, Old Bellevue 6 A606, 550 First Avenue, New York, NY 10016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoClarithromycin-Resistant Genotypes and Eradication of Helicobacter pylori Vincenzo De Francesco , Marcella Margiotta , Angelo Zullo , Cesare Hassan , Laura Troiani , Osvaldo Burattini , Francesca Stella , Alfredo Di Leo , Francesco Russo , Stefania Marangi , Rosa Monno , Vincenzo Stoppino , Sergio Morini , Carmine Panella , and Enzo Ierardi Metrics Cited byNitazoxanide Use as Part of an Empiric Multi-Drug Regimen in Treating Children with Suspected Helicobacter pylori InfectionManagement of Helicobacter pylori infectionAssociatie tussen claritromycine-resistente genotypen en eradicatie van Helicobacter pylori 17 January 2006Volume 144, Issue 2Page: 140-141KeywordsAntibiotic resistanceAntibioticsHelicobacter pyloriLymphoid tissueLymphomaMutationPeptic ulcersPoint mutation ePublished: 17 January 2006 Issue Published: 17 January 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...